Aakaar Medical IPO Itemizing: The shares of medical applied sciences promoting beauty merchandise and gadgets had been entered in the present day at a premium value on NSE SME. Its IPO obtained greater than 2 instances the general. Shares have been issued at a value of ₹ 72 below IPO. Immediately it has entered NSE SME at ₹ 75.00 i.e. IPO buyers received a list achieve of 4.17%. Nonetheless, the enjoyment of IPO buyers pale shortly when the shares broke. It broke down on the decrease circuit of ₹ 71.25 (Aakaar Medical Share Worth) i.e. IPO buyers are actually solely 0.35% revenue. This IPO obtained good response from buyers and total it was subscribed 2.28 instances. It included 3.51 instances the share reserved for certified institutional consumers (QIB), 1.48 instances the share of non-institutional buyers (NII) and 1.93 instances the share of retail buyers. Beneath this IPO, 37,50,400 new shares with face worth of ₹ 10 have been issued. Out of those shares, ₹ 20.35 crore working capital wants and the remainder of the cash can be spent on frequent company functions. Relating to Aakaar Medical Applied sciences, the scale made in 2013 is an Esthetic Medical Firm that sells beauty merchandise and gadgets. Its portfolio additionally has merchandise imported from South Korea, Spain, Italy and Austria along with its personal model. It provides merchandise and gadgets to dermatologists, plastic surgeons and esthetic physicians. Its merchandise are bought in Delhi, Haryana, Punjab, Chandigarh, Uttarakhand, Uttar Pradesh, Bihar, West Bengal, Assam, Gujarat, Madhya Pradesh, Maharashtra, Karnataka, Telangana and Tamil Nadu. It has been strongly strengthened in the case of the monetary well being of the corporate. In FY 2023, it made a web revenue of ₹ 2.15 crore, which jumped within the subsequent monetary 12 months 2024 to ₹ 2.87 crore and ₹ 6.04 crore in FY 2025. Throughout this era, the corporate’s income elevated to ₹ 61.76 crore yearly from the compound price (CAGR) of greater than 37% yearly. Disclaimer: Right here info offered right here is being given just for info. It’s obligatory to say right here that the funding market available in the market is topic to dangers. At all times seek the advice of consultants earlier than investing cash as an investor. There may be by no means recommendation to anybody to speculate cash on behalf of Moneycontrol.
Supply hyperlink
